BRPI0713442A2 - Método para o tratamento de desrodens neurológicas, pelo aumento da atividade de b-glicocerebrosidase - Google Patents
Método para o tratamento de desrodens neurológicas, pelo aumento da atividade de b-glicocerebrosidase Download PDFInfo
- Publication number
- BRPI0713442A2 BRPI0713442A2 BRPI0713442-8A BRPI0713442A BRPI0713442A2 BR PI0713442 A2 BRPI0713442 A2 BR PI0713442A2 BR PI0713442 A BRPI0713442 A BR PI0713442A BR PI0713442 A2 BRPI0713442 A2 BR PI0713442A2
- Authority
- BR
- Brazil
- Prior art keywords
- glucocerebrosidase
- activity
- increasing
- glycerebrosidase
- treatment
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 230000000694 effects Effects 0.000 title abstract 3
- 208000012902 Nervous system disease Diseases 0.000 title abstract 2
- 208000025966 Neurological disease Diseases 0.000 title abstract 2
- 102000004547 Glucosylceramidase Human genes 0.000 abstract 6
- 108010017544 Glucosylceramidase Proteins 0.000 abstract 6
- 108010006519 Molecular Chaperones Proteins 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 230000000144 pharmacologic effect Effects 0.000 abstract 2
- 102000005431 Molecular Chaperones Human genes 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81595206P | 2006-06-23 | 2006-06-23 | |
| US60/815,952 | 2006-06-23 | ||
| PCT/US2007/072016 WO2007150064A2 (en) | 2006-06-23 | 2007-06-25 | METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0713442A2 true BRPI0713442A2 (pt) | 2012-03-06 |
Family
ID=38834440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0713442-8A BRPI0713442A2 (pt) | 2006-06-23 | 2007-06-25 | Método para o tratamento de desrodens neurológicas, pelo aumento da atividade de b-glicocerebrosidase |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US7829579B2 (enExample) |
| EP (1) | EP2040548B1 (enExample) |
| JP (1) | JP5303458B2 (enExample) |
| KR (1) | KR101402554B1 (enExample) |
| AT (1) | ATE555788T1 (enExample) |
| AU (1) | AU2007260812B2 (enExample) |
| BR (1) | BRPI0713442A2 (enExample) |
| CA (1) | CA2656643C (enExample) |
| DK (1) | DK2040548T3 (enExample) |
| ES (1) | ES2387845T3 (enExample) |
| IL (1) | IL196151A (enExample) |
| MX (1) | MX2009000032A (enExample) |
| PT (1) | PT2040548E (enExample) |
| WO (1) | WO2007150064A2 (enExample) |
| ZA (1) | ZA200900270B (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7138262B1 (en) | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
| KR101402554B1 (ko) | 2006-06-23 | 2014-06-19 | 아미쿠스 세라퓨틱스, 인코포레이티드 | β-글루코세레브로시다제의 활성 증진에 의한 신경계 장애 치료 방법 |
| GB0622702D0 (en) * | 2006-11-15 | 2006-12-27 | Univ Dundee | Selective glycosidase inhibitors |
| PL2154969T3 (pl) | 2007-05-16 | 2016-04-29 | Brigham & Womens Hospital Inc | Leczenie synukleinopatii |
| PL2659904T3 (pl) | 2008-06-26 | 2016-01-29 | Orphazyme Aps | Zastosowanie Hsp70 jako regulatora aktywności enzymatycznej |
| US20120052053A1 (en) * | 2008-11-14 | 2012-03-01 | Manning-Bog Amy B | Compositions and methods for the treatment of altered alpha-synuclein function |
| GB0906159D0 (en) * | 2009-04-09 | 2009-05-20 | Summit Corp Plc | Drug combination for the treatment of proteostatic diseases |
| CA2758271C (en) * | 2009-04-09 | 2018-06-05 | Robert Boyd | Methods for preventing and/or treating lysosomal storage disorders |
| US8304429B2 (en) * | 2009-04-09 | 2012-11-06 | Amicus Therapeutics, Inc. | Methods for preventing and/or treating degenerative disorders of the central nervous system |
| US9206457B2 (en) * | 2009-05-26 | 2015-12-08 | Amicus Therapeutics, Inc. | Utilization of pharmacological chaperones to improve manufacturing and purification of biologics |
| EP2435459B1 (en) * | 2009-05-26 | 2016-05-04 | Amicus Therapeutics, Inc. | Utilization of pharmacological chaperones to improve manufacturing and purification of acid beta-glucosidase |
| CN105126086B (zh) * | 2009-07-28 | 2019-05-14 | 夏尔人类遗传性治疗公司 | 用于治疗戈谢病的组合物和方法 |
| EP2490533B1 (en) | 2009-10-19 | 2015-09-16 | Amicus Therapeutics, Inc. | Novel compositions for preventing and/or treating lysosomal storage disorders |
| RU2015147509A (ru) | 2009-10-19 | 2019-01-14 | Амикус Терапьютикс, Инк. | Новые композиции для предупреждения и/или лечения дегенеративных расстройств центральной нервной системы |
| WO2011049787A1 (en) * | 2009-10-19 | 2011-04-28 | Amicus Therapeutics, Inc. | Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases |
| DK2646044T3 (da) | 2010-11-30 | 2019-11-25 | Orphazyme As | Metoder til at øge den intracellulære aktivitet af Hsp70 |
| WO2012154967A1 (en) | 2011-05-12 | 2012-11-15 | Proteostasis Therapeutics, Inc. | Proteostasis regulators |
| EP2533051A1 (en) | 2011-06-06 | 2012-12-12 | Centogene GmbH | Method for the diagnosis of Gaucher's disease |
| CN103764166B (zh) | 2011-06-22 | 2017-10-24 | 通用医疗公司 | 蛋白质病的治疗 |
| JP2015504919A (ja) | 2012-01-25 | 2015-02-16 | プロテオステイシス セラピューティクス，インコーポレイテッド | プロテアソーム活性を調節する化合物 |
| MA38144A1 (fr) * | 2012-11-05 | 2018-08-31 | Genzyme Corp | Compositions et procédés pour le traitement de protéinopathies |
| US9750712B2 (en) | 2012-12-07 | 2017-09-05 | Rush University Medical Center | Composition and method for treating neuronal ceroid lipofuscinosis |
| EP3087056A4 (en) | 2013-12-23 | 2017-07-19 | Alectos Therapeutics Inc. | Glucocerebrosidase modulators and uses thereof |
| US9675627B2 (en) | 2014-04-14 | 2017-06-13 | Amicus Therapeutics, Inc. | Dosing regimens for treating and/or preventing cerebral amyloidoses |
| KR20250069686A (ko) | 2014-09-15 | 2025-05-19 | 제브라 덴마크 에이/에스 | 아리모클로몰 제제 |
| PT3215511T (pt) | 2014-11-06 | 2024-05-22 | Bial R&D Invest S A | Pirazolo(1,5-a)pirimidinas substituídas e a sua utilização no tratamento de distúrbios médicos |
| EP3292206B8 (en) | 2015-05-07 | 2022-02-09 | Takeda Pharmaceutical Company Limited | Glucocerebrosidase gene therapy for parkinson's disease |
| EP3440080A4 (en) | 2016-04-06 | 2020-01-22 | Lysosomal Therapeutics Inc. | PYRAZOLO [1,5-A] PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| WO2017176962A1 (en) | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics, Inc. | Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| MX2018012208A (es) | 2016-04-06 | 2019-03-28 | Lysosomal Therapeutics Inc | Compuestos a base de imidazo [1,5-a] pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos. |
| US10898476B2 (en) | 2016-04-13 | 2021-01-26 | Orphazyme A/S | Heat shock proteins and cholesterol homeostasis |
| LT3448382T (lt) | 2016-04-29 | 2021-04-12 | Orphazyme A/S | Arimoklomolis, skirtas su gliukocerebrozidaze susijusiems sutrikimams gydyti |
| JP7164774B2 (ja) | 2016-05-05 | 2022-11-02 | ビアル－アール・アンド・ディ・インベストメンツ・ソシエダーデ・アノニマ | 置換イミダゾ［１，２－ｂ］ピリダジン、置換イミダゾ［１，５－ｂ］ピリダジン、関連化合物、および医学的障害の治療におけるその使用 |
| EP3264092A1 (en) * | 2016-07-01 | 2018-01-03 | Centogene AG | Use of lyso-gb1 as druggable target |
| KR20240171186A (ko) | 2017-10-26 | 2024-12-06 | 다케다 야쿠힌 고교 가부시키가이샤 | 글루코세레브로시다제 및 이소파고민을 포함하는 제제 |
| CN108428452B (zh) | 2018-03-14 | 2019-12-13 | 百度在线网络技术（北京）有限公司 | 终端支架和远场语音交互系统 |
| BR122023023216A2 (pt) | 2018-06-27 | 2024-02-20 | Proteostasis Therapeutics, Inc. | Compostos, composição farmacêutica e uso de uma quantidade eficaz de um composto |
| CN112585130A (zh) | 2018-06-27 | 2021-03-30 | 蛋白质平衡治疗股份有限公司 | 蛋白酶体活性增强化合物 |
| WO2020023390A1 (en) | 2018-07-25 | 2020-01-30 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
| WO2020118056A1 (en) * | 2018-12-05 | 2020-06-11 | Washington University | Methods of detecting, preventing, reversing, and treating neurological diseases |
| WO2020219874A1 (en) | 2019-04-25 | 2020-10-29 | Shire Human Genetic Therapies, Inc. | Isofagomine salts, methods of use and formulations |
| CN111450306B (zh) * | 2020-03-06 | 2021-11-19 | 大连理工大学 | 外用纳米羟基磷灰石/聚多巴胺湿黏附型止血粉及其制备方法 |
| US20230416224A1 (en) | 2020-11-19 | 2023-12-28 | Zevra Denmark A/S | Processes for preparing arimoclomol citrate and intermediates thereof |
| AU2022265691A1 (en) * | 2021-04-30 | 2023-11-09 | Vanqua Bio, Inc. | Small molecule modulators of glucocerebrosidase activity and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0934531B1 (en) * | 1996-10-15 | 2004-08-04 | D-Gen Limited | Diagnosis of spongiform encephalopathy |
| GB2355074A (en) | 1996-10-15 | 2001-04-11 | Imperial College | Method for predicting susceptibility to bovine spongiform encephalopathy |
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| PT2444102E (pt) | 2003-01-31 | 2015-09-17 | Sinai School Medicine | Terapia combinada para o tratamento de distúrbios de deficiência proteica |
| US20050137223A1 (en) | 2003-11-12 | 2005-06-23 | Amicus Therapeutics, Inc. | Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease |
| AU2006254796B2 (en) | 2005-06-08 | 2012-08-16 | Amicus Therapeutics, Inc. | Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes |
| WO2007140212A2 (en) * | 2006-05-24 | 2007-12-06 | Amicus Therapeutics, Inc. | Tartrate salt of isofagomine and methods of use |
| KR101402554B1 (ko) | 2006-06-23 | 2014-06-19 | 아미쿠스 세라퓨틱스, 인코포레이티드 | β-글루코세레브로시다제의 활성 증진에 의한 신경계 장애 치료 방법 |
| KR101597499B1 (ko) | 2007-05-22 | 2016-02-24 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 이소파고민과 이의 유도체를 제조하는 새로운 방법 |
-
2007
- 2007-06-25 KR KR1020097001465A patent/KR101402554B1/ko not_active Expired - Fee Related
- 2007-06-25 MX MX2009000032A patent/MX2009000032A/es active IP Right Grant
- 2007-06-25 ES ES07812295T patent/ES2387845T3/es active Active
- 2007-06-25 PT PT07812295T patent/PT2040548E/pt unknown
- 2007-06-25 CA CA2656643A patent/CA2656643C/en not_active Expired - Fee Related
- 2007-06-25 AU AU2007260812A patent/AU2007260812B2/en active Active
- 2007-06-25 EP EP20070812295 patent/EP2040548B1/en active Active
- 2007-06-25 AT AT07812295T patent/ATE555788T1/de active
- 2007-06-25 BR BRPI0713442-8A patent/BRPI0713442A2/pt not_active Application Discontinuation
- 2007-06-25 DK DK07812295T patent/DK2040548T3/da active
- 2007-06-25 US US11/768,043 patent/US7829579B2/en active Active
- 2007-06-25 WO PCT/US2007/072016 patent/WO2007150064A2/en not_active Ceased
- 2007-06-25 JP JP2009518489A patent/JP5303458B2/ja active Active
-
2008
- 2008-12-23 IL IL196151A patent/IL196151A/en active IP Right Grant
-
2009
- 2009-01-13 ZA ZA2009/00270A patent/ZA200900270B/en unknown
-
2010
- 2010-11-08 US US12/941,468 patent/US9119845B2/en active Active
-
2014
- 2014-08-26 US US14/469,008 patent/US9402837B2/en active Active
-
2016
- 2016-08-01 US US15/225,029 patent/US10064851B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PT2040548E (pt) | 2012-08-02 |
| AU2007260812A1 (en) | 2007-12-27 |
| CA2656643A1 (en) | 2007-12-27 |
| KR101402554B1 (ko) | 2014-06-19 |
| ZA200900270B (en) | 2011-02-23 |
| US20170027919A1 (en) | 2017-02-02 |
| US20110052613A1 (en) | 2011-03-03 |
| JP5303458B2 (ja) | 2013-10-02 |
| DK2040548T3 (da) | 2012-08-13 |
| WO2007150064A2 (en) | 2007-12-27 |
| US7829579B2 (en) | 2010-11-09 |
| EP2040548A4 (en) | 2009-12-23 |
| CA2656643C (en) | 2015-08-25 |
| US20080009516A1 (en) | 2008-01-10 |
| WO2007150064A3 (en) | 2008-02-21 |
| KR20090021393A (ko) | 2009-03-03 |
| ATE555788T1 (de) | 2012-05-15 |
| US20150025109A1 (en) | 2015-01-22 |
| AU2007260812B2 (en) | 2012-08-16 |
| ES2387845T3 (es) | 2012-10-02 |
| JP2009541489A (ja) | 2009-11-26 |
| US10064851B2 (en) | 2018-09-04 |
| EP2040548A2 (en) | 2009-04-01 |
| IL196151A (en) | 2015-08-31 |
| US9119845B2 (en) | 2015-09-01 |
| MX2009000032A (es) | 2009-01-23 |
| US9402837B2 (en) | 2016-08-02 |
| EP2040548B1 (en) | 2012-05-02 |
| IL196151A0 (en) | 2009-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0713442A2 (pt) | Método para o tratamento de desrodens neurológicas, pelo aumento da atividade de b-glicocerebrosidase | |
| MX352412B (es) | Tratamiento de enfermedades relacionadas con eritropoyetina (epo) mediante inhibicion del transcrito antisentido natural a eritropoyetina. | |
| MX2010004074A (es) | Combinacion 059. | |
| CY1108927T1 (el) | Αναστολεις μιτωτικης κινεσινης | |
| MX339820B (es) | Compuestos oligonucleottidos designados para inhibir el transcrito antisentido natrual apra apolipoproteina-a1. | |
| EA201170847A1 (ru) | Тиазолопиридиновые соединения, регулирующие сиртуин | |
| MX2021012184A (es) | Terapias genicas para trastornos lisosomales. | |
| NO20050198L (no) | Mitotiske kinesininhibitorer | |
| WO2010065662A3 (en) | Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1 | |
| DE60324449D1 (de) | Inhibitoren der phosphodiesterase der zyklischen n, und deren verwendung in therapie | |
| ATE516353T1 (de) | Verwendung von rnai mit inhibierender parp aktivität zur herstelllung eines arzneimittels zur behandlung von krebs | |
| MX364651B (es) | Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmacéuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabéticos tipificados genéticamente. | |
| MX2009006672A (es) | Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol. | |
| WO2009068659A3 (en) | Novel disease treatment by predicting drug association | |
| AU2009279857A8 (en) | Modulation of toll-like receptor 3 expression by antisense oligonucleotides | |
| BR112022021957A2 (pt) | Imidazopirimidinas como moduladores de il -17 | |
| BR112022021964A2 (pt) | Ácidos nucleicos modificados que codificam aspartoacilase (aspa) e vetores para terapia gênica | |
| MX2023001562A (es) | Terapias genicas para trastornos lisosomales. | |
| MX2024001269A (es) | Inhibidores de rock2 y sus usos. | |
| BRPI0514397A (pt) | derivados de 3-ariltioindol-2-carboxamida e análogos destes como inibidores de caseìna cinase iépsilon | |
| WO2010065536A3 (en) | Recombinant bone marrow stromal antigen-2 in the treatment of autoimmune diseases | |
| ATE529514T1 (de) | Sirna zur hemmung der il-6-expression und diese enthaltende zusammensetzung | |
| ATE554069T1 (de) | Verwendung von tetrahydropyridinen zur behandlung von erkrankungen des zentralnervensystems | |
| WO2008126085A3 (en) | Method for treating bone marrow disorders | |
| EA202192737A1 (ru) | Генная терапия лизосомальных нарушений |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |